Ningbo Kunpeng Biotech Co., Ltd. was established in April 2016. The company takes "providing medicines, technologies and services for human disease control" as its mission and is committed to the research, development, production and sales of human drugs.
In the field of diabetes treatment drugs, the company has developed a product including recombinant human insulin, insulin glargine, insulin aspart, liraglutide and other pharmaceutical products using the unique "protein fixed-point modification technology" platform and subversive process engineering technology development. chain. At the same time, research on new drugs such as new long-acting insulin and GLP-1 analogs is also actively underway.
The company has a complete R&D and pilot test platform, and has formed a team of R&D, production and quality management talents including several domestic and foreign technical experts. In the first phase of industrialization, RMB 200 million was invested. The high-end biopharmaceutical industrialization base built according to the GMP standards of NMPA, US FDA and EU EMA is expected to be put into use in 2021, with an annual output of more than 30 million drugs and an output value of RMB 1.5 billion. The company's industrialization phase II is 120 acres, with an annual output value of 15 billion.
In the next 5 years, the company will obtain clinical approvals with 3 varieties per year by virtue of efficient R&D system, advanced production technology and international quality management. As well as drugs for global disease treatment needs, it has become a leading domestic biopharmaceutical company.